Cytokinetics Inc’s filing revealed that its Director WIERENGA WENDELL unloaded Company’s shares for reported $1.32 million on Dec 22 ’25. In the deal valued at $66.14 per share,20,000 shares were sold. As a result of this transaction, WIERENGA WENDELL now holds 32,444 shares worth roughly $2.05 million.
Then, WENDELL WIERENGA bought 20,000 shares, generating $1,254,400 in total proceeds.
Before that, Malik Fady Ibraham sold 2,200 shares. Cytokinetics Inc shares valued at $134,728 were divested by the EVP Research & Development at a price of $61.24 per share. As a result of the transaction, Malik Fady Ibraham now holds 138,552 shares, worth roughly $8.77 million.
Goldman upgraded its Cytokinetics Inc [CYTK] rating to a Buy from a a Neutral in a research note published recently. Barclays began covering CYTK with “an Overweight” recommendation on April 24, 2025. Citigroup started covering the stock on February 07, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -3.52% to $63.29. Over the last five days, the stock has gained 2.05%. Cytokinetics Inc shares have risen nearly 35.41% since the year began. Nevertheless, the stocks have risen 34.55% over the past one year. While a 52-week high of $70.98 was reached on 12/22/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 61.77, which if violated will result in even more drops to 60.25. On the upside, there is a resistance level at 65.04. A further resistance level may holdings at 66.78.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-11-28, dropping by -0.84 million shares to a total of 12.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 13.79 million shares. There was a decline of -6.47%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 22, 2025 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $80 price target.
